Background: Despite an increase in the number of therapies available to treat patients with
immune thrombocytopenia (ITP), there are minimal data from randomized trials to assist …

Over the last decade, there have been numerous developments and changes in treatment
practices for the management of patients with immune thrombocytopenia (ITP). This article is …

The two thrombopoietin receptor agonists (TPO-RA), eltrombopag and romiplostim, were
licensed in the US for treatment of immune thrombocytopenia (ITP) in 2008 and, since then …

Background The burden of severe bleeding in adults and children with immune
thrombocytopenia (ITP) has not been established. Objectives To describe the frequency and …

Thrombocytopenia results from a variety of conditions, including radiation, chemotherapy,
autoimmune disease, bone marrow disorders, pathologic conditions associated with …

Immune thrombocytopenia (ITP) is an autoimmune process resulting in increased
destruction and inadequate production of platelets that can result in bleeding, fatigue, and …

Immune thrombocytopenia (ITP) is an autoimmune disorder in which a combination of
defective platelet production and enhanced clearance leads to thrombocytopenia. The …

The thrombopoietin receptor agonists (TPO-RAs) are a class of platelet growth factors
commonly used to treat immune thrombocytopenia (ITP). There are three agents that have …

Immune thrombocytopenia (ITP) is an autoimmune bleeding disorder affecting
approximately 1 in 20,000 people. Patients typically present with clinically benign …

Primary immune thrombocytopenia is an autoimmune disorder of unknown cause affecting
both children and adults. The low peripheral blood platelet count is caused by premature …